文献速递神经肿瘤

靶向HTR2B通过抑制Gαq/PLC/PKCγ/STAT3轴抑制无功能垂体腺瘤生长并增强卡麦角林治疗敏感性

Targeting HTR2B suppresses nonfunctioning pituitary adenoma growth and sensitizes cabergoline treatment via inhibiting Gαq/PLC/PKCγ/STAT3 axis.
PubMed 文献 · Neuro Oncol · 2024-01-01

研究分析无功能垂体腺瘤(NFPA)中HTR2B的表达与作用,发现NFPA样本HTR2B表达升高且与肿瘤存活增加相关;抑制HTR2B可经Gαq/PLC/PKCγ/STAT3轴阻断STAT3活化并抑制肿瘤生长,HTR2B拮抗剂PRX-08066与卡麦角林(CAB)联用在细胞系、异种移植模型及患者来源样本中显著抑制肿瘤细胞增殖。

要点

  • NFPA样本中HTR2B表达升高,且与肿瘤存活增加相关。
  • PRX-08066抑制HTR2B,经Gαq/PLC/PKC通路阻断STAT3磷酸化与核转位。
  • CAB经HTR2B激活pSTAT3而削弱疗效,HTR2B拮抗剂与CAB联用显著抑制肿瘤细胞增殖。

核心结论

  • HTR2B是NFPA的潜在治疗靶点,抑制HTR2B可提高CAB疗效。
  • 对HTR2B高表达的NFPA患者,双药联合治疗可能有益。

研究设计与样本

  • 研究对bulk RNA测序数据进行筛选,分析NFPA样本中HTR2B的表达水平。
  • 开展体外与体内实验,评估调控HTR2B对肿瘤生长和细胞周期的作用。
  • 利用药理学抑制剂和分子互作实验阐明HTR2B介导的信号通路。
  • 在HTR2B表达阳性的垂体肿瘤细胞系、异种移植垂体肿瘤模型及患者来源样本中验证联合治疗。

主要发现

  • NFPA样本中检出HTR2B表达升高,且与肿瘤存活增加相关。
  • 抑制HTR2B活性通过调控G2M细胞周期抑制肿瘤生长。
  • PRX-08066抑制HTR2B,经干扰Gαq/PLC/PKC通路阻断STAT3磷酸化与核转位。
  • PKC-γ与STAT3的直接互作对STAT3活化至关重要。
  • CAB经HTR2B激活pSTAT3,降低其治疗潜力;HTR2B拮抗剂与CAB联用在上述模型中显著抑制肿瘤细胞增殖。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Managing nonfunctioning pituitary adenomas (NFPAs) is difficult due to limited drug treatments. Cabergoline's (CAB) effectiveness for NFPAs is debated. This study explores the role of HTR2B in NFPAs and its therapeutic potential. METHODS: We conducted screening of bulk RNA-sequencing data to analyze HTR2B expression levels in NFPA samples. In vitro and in vivo experiments were performed to evaluate the effects of HTR2B modulation on tumor growth and cell cycle regulation. Mechanistic insights into the HTR2B-mediated signaling pathway were elucidated using pharmacological inhibitors and molecular interaction assays. RESULTS: Elevated HTR2B expression was detected in NFPA samples, which was associated with increased tumor survival. Inhibition of HTR2B activity resulted in the suppression of tumor growth through modulation of the G2M cell cycle. The inhibition of HTR2B with PRX-08066 was found to block STAT3 phosphorylation and nuclear translocation by interfering with the Gαq/PLC/PKC pathway. A direct interaction between PKC-γ and STAT3 was critical for STAT3 activation. CAB was shown to activate pSTAT3 via HTR2B, reducing its therapeutic potential. However, the combination of an HTR2B antagonist with CAB significantly inhibited tumor cell proliferation in HTR2B-expressing pituitary tumor cell lines, a xenografted pituitary tumor model, and patient-derived samples. Analysis of patient-derived data indicated that a distinct molecular pattern characterized by upregulated HTR2B/PKC-γ and downregulated BTG2/GADD45A may benefit from combination treatment with CAB and PRX-08066. CONCLUSIONS: HTR2B is a potential therapeutic target for NFPAs, and its inhibition could improve CAB efficacy. A dual therapy approach may be beneficial for NFPA patients with high HTR2B expression.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Lin S, Wang L, Han C, et al. Targeting HTR2B suppresses nonfunctioning pituitary adenoma growth and sensitizes cabergoline treatment via inhibiting Gαq/PLC/PKCγ/STAT3 axis. Neuro Oncol. 2024. PMID: 38989697. doi:10.1093/neuonc/noae130

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。